Plasma procoagulant phospholipid clotting time and venous thromboembolism risk

BACKGROUND: Negatively charged procoagulant phospholipids, phosphatidylserine (PS) in particular, are vital to coagulation and expressed on the surface membrane of extracellular vesicles. No previous study has investigated the association between plasma procoagulant phospholipid clotting time (PPL(C...

Full description

Bibliographic Details
Published in:Research and Practice in Thrombosis and Haemostasis
Main Authors: Ramberg, Cathrine, Wilsgård, Line, Latysheva, Nadezhda, Brækkan, Sigrid K., Hindberg, Kristian, Sovershaev, Timofey, Snir, Omri, Hansen, John‐Bjarne
Format: Text
Language:English
Published: John Wiley and Sons Inc. 2021
Subjects:
Original Articles
Tromsø
Online Access:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686193/
https://doi.org/10.1002/rth2.12640
Description
Summary:BACKGROUND: Negatively charged procoagulant phospholipids, phosphatidylserine (PS) in particular, are vital to coagulation and expressed on the surface membrane of extracellular vesicles. No previous study has investigated the association between plasma procoagulant phospholipid clotting time (PPL(CT)) and future risk of venous thromboembolism (VTE). OBJECTIVES: To investigate the association between plasma PPL(CT) and the risk of incident VTE in a nested case‐control study. METHODS: We conducted a nested case‐control study in 296 VTE patients and 674 age‐ and sex‐matched controls derived from a general population cohort (The Tromsø Study 1994–2007). PPL(CT) was measured in platelet‐free plasma using a modified factor Xa‐dependent clotting assay. Logistic regression was used to estimate odds ratio (OR) with 95% confidence intervals (CI) for VTE with PPL(CT) modelled as a continuous variable across quartiles and in dichotomized analyses. RESULTS: There was a weak inverse association between plasma PPL(CT) and risk of VTE per 1 standard deviation increase of PPL(CT) (OR 0.93, 95% CI 0.80–1.07) and when comparing those with PPL(CT) in the highest quartile (OR 0.89, 95% CI 0.60–1.30) with those in the lowest quartile. Subjects with PPL(CT) >95th percentile had substantially lowered OR for VTE (OR 0.35, 95% CI 0.13–0.81). The inverse association was stronger when the analyses were restricted to samples taken shortly before the event. The risk estimates by categories of plasma PPL(CT) were similar for deep vein thrombosis and pulmonary embolism. CONCLUSION: Our findings suggest that high plasma PPL(CT) is associated with reduced risk of VTE.

Similar Items